Dystrophin Immunity in Duchenne's Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the first mini-dystrophin clinical trial (NCT00428935), completed in 2010, most parsimoniously failed due to immune responses developed against the transgene, which was delivered in the biceps muscle using the AAV2.5 vector [122].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [122]
In the citing paper
“To date, transgene immune responses in AAV gene therapy have been mostly reported in muscle-directed clinical trials [94, 115–119].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
In the citing paper
“In clinical trials, CD8+ T cell responses have been observed against dystrophin and α1-antitrypsin in treatment of Duchenne’s muscular dystrophy and α1-antitrypsin (AAT) deficiency, respectively (55, 56).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citation
Research works printed but not linked: 1
- Klein CJ, 1992, Am J Hum Genet, 50, 950
Cited by
Items 301–400 of 680
Mariz, F. P., Carvalho, L. R., Araújo, A. P. D. Q. C., de Mello, W., Ribeiro, M. G., Cunha, M. D. C. S. A., Cabello, P. H., Riederer, I., Négroni, E., Desguerre, I., et al. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0066-2 · Cited by 28
“Inhibition of CD49d-mediated interactions could be envisioned as a novel therapeutic strategy for improving disease progression in DMD patients, by decreasing the immune response, in conjunction with other gene therapy approaches such as exon skipping or gene replacement, which in some cases triggers dystrophin-specif…”
BackgroundDystrophic Cardiomyopathy—Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies
Johnstone, V., Viola, H. M., & Hool, L. C. (2017) · Genes · doi:10.3390/genes8040108 · Cited by 28
Tran, D. M., Harrang, J., Song, S., Chen, J., Smith, B. M., & Miao, C. H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.012 · Cited by 28
Bengtsson, N. E., Tasfaout, H., Hauschka, S. D., & Chamberlain, J. S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.003 · Cited by 29
Lompré, A.-M., Hadri, L., Merlet, E., Keuylian, Z., Mougenot, N., Karakikes, I., Chen, J., Atassi, F., Marchand, A., Blaise, R., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.13 · Cited by 30
Self-citationHutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
Bertoni, C., & Namgoong, J. (2016) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s71808 · Cited by 34
The emerging role of viral vectors as vehicles for DMD gene editing
Maggio, I., Chen, X., & Gonçalves, M. A. F. V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0316-x · Cited by 27
“In part related to this potential issue, T-cell immunity directed to epitopes corresponding to wild-type dystrophin sequences was detected in two patients undergoing a clinical trial based on recombinant adeno-associated viral vector (rAAV) delivery of a microdystrophin construct [31].”
P2X7 purinoceptor as a therapeutic target in muscular dystrophies
Górecki, D. C. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.02.003 · Cited by 27
Poupiot, J., Costa Verdera, H., Hardet, R., Colella, P., Collaud, F., Bartolo, L., Davoust, J., Sanatine, P., Mingozzi, F., Richard, I., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.012 · Cited by 24
“immunity to the encoded transgene(34) can exacerbate transgene immunity and result in loss of transduced muscle fibers.(17) Interestingly, experience with AAV vector-mediated muscle gene transfer in smalland large-animal models indicates that there is a direct relationship between transgene immunogenicity and route of…”
BackgroundDuan, D. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.001 · Cited by 31
“Another AAV trial was reported in 2010 for DMD.(25) This trial used an engineered AAV-2.”
InfluentialBartolo, L., Li Chung Tong, S., Chappert, P., Urbain, D., Collaud, F., Colella, P., Richard, I., Ronzitti, G., Demengeot, J., Gross, D. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127008 · Cited by 23
“Muscle monogenic disorders can induce tissue inflammation and particularly in patients with DMD (25), where contraction-induced damages release cytoplasmic content that can stimulate innate immunity, promote chronic muscle inflammation, and worsen adverse immune responses to the therapeutic transgene (51).”
BackgroundInfluentialCRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
Chey, Y. C. J., Arudkumar, J., Aartsma-Rus, A. M., Adikusuma, F., & Thomas, P. Q. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1580 · Cited by 28
Kaziród, K., Myszka, M., Dulak, J., & Łoboda, A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04636-0 · Cited by 26
“Despite positive effects in animal studies, the clinical efficacy of this strategy was not sufficient and problems with a very low level of micro-dystrophin in the muscles and an unsatisfactory transduction efficiency of the diaphragm and particularly the heart were evident [65].”
BackgroundtRNA modifications and tRNA-derived small RNAs: new insights of tRNA in human disease
Wu, D., Li, X., Khan, F. A., Yuan, C., Pandupuspitasari, N. S., Huang, C., Sun, F., & Guan, K. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09919-9 · Cited by 27
Current prospects and challenges for epilepsy gene therapy
Weinberg, M. S., & McCown, T. J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.003 · Cited by 25
“Unlike genetic disorders such as hemophilia or Duchenne's muscular dystrophy, for which gene therapy offers promise of specific gene correction (Manno et al., 2006; Mendell et al., 2010), intractable epilepsy often occurs without any known genetic linkage.”
BackgroundFan, Z., Kocis, K. C., Valley, R. D., Howard, J. F., Chopra, M., Chen, Y., An, H., Lin, W., Muenzer, J., & Powers, W. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.023 · Cited by 24
Therapeutic applications of CRISPR RNA-guided genome editing
Koo, T., & Kim, J. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw032 · Cited by 26
Lane, R. J. M., Roncaroli, F., Charles, P. J., McGonagle, D., & Orrell, R. W. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.06.751 · Cited by 24
“patients prior to treatment with a dystrophin minigene vector [42].”
BackgroundLin, A. Y., Próchniewicz, E., Henderson, D. M., Li, B., Ervasti, J. M., & Thomas, D. D. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.04.005 · Cited by 30
Hordeaux, J., Ramezani, A., Tuske, S., Mehta, N., Song, C., Lynch, A., Lupino, K., Chichester, J. A., Buza, E. L., Dyer, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094279 · Cited by 23
“However, T-cell responses to the transgene product following AAV gene therapy have received much less attention and have been primarily documented in Duchenne muscular dystrophy trials (3, 4).”
BackgroundGenome Editing in Neurosciences
Jaenisch, R., Gage, F. H., & Zhang, F. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2 · Cited by 24
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Teng, T., Song, X., Sun, G., Ding, H., Sun, H., Bai, G., & Shi, B. (2022) · Animal nutrition · doi:10.1016/j.aninu.2022.10.009 · Cited by 24
“Dystrophin is a macromolecular cytoskeletal protein widely used to evaluate muscle diseases or dysplasia (Mendell et al., 2010; Carter et al., 2018).”
BackgroundGene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments
Mbakam, C. H., & Tremblay, J. P. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2249607 · Cited by 24
“Moreover, T cell response against dystrophin was also reported in patients who received an intramuscular (in bicep) injection of rAAV2-minidystrophin transgene [37].”
BackgroundGenome Editing Gene Therapy for Duchenne Muscular Dystrophy
Hotta, A. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150116 · Cited by 25
“Immune responses against the corrected dystrophin protein must also be take into consideration [97].”
BackgroundNoviello, M., Tedesco, F. S., Bondanza, A., Tonlorenzi, R., Carbone, M. R., Gerli, M., Marktel, S., Napolitano, S., Cicalese, M. P., Ciceri, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.62 · Cited by 25
Gene and splicing therapies for neuromuscular diseases
Goyenvalle, A. (2015) · Frontiers in bioscience · doi:10.2741/4367 · Cited by 27
“vector designed to be a serotype 2 capsid variant that contains 5 AAV1 amino acids (1 insertion and 4 substitutions) in the AAV2 VP1 background (71).”
BackgroundDevelopment of a Single Construct System for Site-Directed RNA Editing Using MS2-ADAR
Tohama, T., Sakari, M., & Tsukahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144943 · Cited by 25
“56 vector copies per diploid genome [26].”
Ho, P. P.-K., Lahey, L. J., Mourkioti, F., Kraft, P. E., Filareto, A., Brandt, M., Magnusson, K. E. G., Finn, E. E., Chamberlain, J. S., Robinson, W. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808648115 · Cited by 22
“(17) found modest dystrophin-specific T cell immunity in patients with DMD both before and after gene therapy in a human clinical trial.”
BackgroundTucker, J. D., Lu, P., Xiao, X., & Lu, Q. L. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.008 · Cited by 22
“Furthermore, an early clinical trial with a truncated dystrophin reports cytotoxic T cell response, which is associated with unexpected low levels of transgene expression, although the exact mechanism for the immune response remains unclear.(43,44) Gene therapy expressing a protein variant with only 3 amino acid diffe…”
BackgroundSelf-citationDrug‐induced liver injury related to gene therapy: A new challenge to be managed
Larrey, D. G., Delire, B., Meunier, L., Zahhaf, A., Martin, E. D., & Horsmans, Y. (2024) · Liver International · doi:10.1111/liv.16065 · Cited by 26
“47 Furthermore, in patients treated for α 1-antitrypsin deficiency who received intramuscular gene transfer, anti-capsid T cells were detected in the majority of patients.”
Hashimoto, H., Mizushima, T., Chijiwa, T., Nakamura, M., & Suemizu, H. (2017) · Virus Research · doi:10.1016/j.virusres.2017.05.017 · Cited by 21
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
Marshall, J. L., Kwok, Y., McMorran, B. J., Baum, L. G., & Crosbie, R. H. (2013) · FEBS Journal · doi:10.1111/febs.12295 · Cited by 23
Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy
Scully, M. A., Pandya, S., & Moxley, R. T. (2012) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.746939 · Cited by 26
Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes
Tedesco, F. S. (2015) · Chromosome Research · doi:10.1007/s10577-014-9460-6 · Cited by 22
French, R. A., Samelson-Jones, B. J., Niemeyer, G. P., Lothrop, C. D., Merricks, E. P., Nichols, T. C., & Arruda, V. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015313 · Cited by 21
“Thus, a comprehensive evaluation showed no immune response to FIX-Padua in a highly provocative scenario, combining the most challenging animal model(8) with a target tissue that is not predisposed to immune tolerance.(22) Moreover, 1 UNC-CH dog (O20) received an inadvertent subtherapeutic dose of the same vector (Fig…”
BackgroundDevelopment of Therapeutic RNA Manipulation for Muscular Dystrophy
Saifullah, S., Motohashi, N., Tsukahara, T., & Aoki, Y. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.863651 · Cited by 22
Selot, R., Arumugam, S., Mary, B., Cheemadan, S., & Jayandharan, G. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00441 · Cited by 20
“…therapy using recombinant Adeno-associated virus (Serotypes AAV1 to AAV12) has gained significant attention after early success with several pre-clinical and clinical studies (De et al., 2006; Zincarelli et al., 2008; Mendell et al., 2010; Mingozzi and High, 2011; Nathwani et al., 2011).”
BackgroundAdvances in gene therapy for muscular dystrophies
Abdul-Razak, H. H., Malerba, A., & Dickson, G. (2016) · F1000Research · doi:10.12688/f1000research.8735.1 · Cited by 21
What’s new and what’s next for gene therapy in Pompe disease?
Roger, A. L., Sethi, R., Huston, M. L., Scarrow, E. R., Bao-Dai, J., Lai, E., Biswas, D. D., Haddad, L. E., Strickland, L. M., Kishnani, P. S., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2067476 · Cited by 20
“demonstrate the need for systemic treatment[146,147,175,176].”
BackgroundA longitudinal study of creatine kinase and creatinine levels in Duchenne muscular dystrophy
Zygmunt, A., Wong, B. L. Y., Horn, P. S., Lambert, J., Bange, J. E., Rybalsky, I., Chouteau, W. A., & Tian, C. (2022) · Muscle & Nerve · doi:10.1002/mus.27760 · Cited by 19
Stirm, M., Shashikadze, B., Blutke, A., Kemter, E., Lange, A., Stöckl, J. B., Jaudas, F., Laane, L., Kurome, M., Keßler, B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301250120 · Cited by 22
“There is evidence in both DMD patients (30) and dystrophin-deficient animal models (31) that dystrophin restoration can lead to an anti-dystrophin immune response.”
Qiao, C., Yuan, Z., Li, J., Tang, R., Li, J., & Xiao, X. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.229 · Cited by 22
“…such as hemophilia B (Manno et al., 2003; Nathwani et al., 2011), Leber’s congenital amaurosis (Hauswirth et al., 2008; Maguire et al., 2008, 2009), Parkinson’s disease (Kaplitt et al., 2007), and hereditary muscular dystrophies (Wang et al., 2000; Harper et al., 2002; Mendell et al., 2009, 2010).”
BackgroundSelf-citationBioengineered Viral Platform for Intramuscular Passive Vaccine Delivery to Human Skeletal Muscle
Paulk, N. K., Pekrun, K., Charville, G. W., Maguire, K., Wosczyna, M. N., Xu, J., Zhang, Y., Lisowski, L., Yoo, B., Vilches-Moure, J. G., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.001 · Cited by 20
Kraszewska, I., Tomczyk, M., Andrysiak, K., Biniecka, M., Geisler, A., Fechner, H., Zembala, M. O., Stępniewski, J., Dulak, J., & Jaźwa, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.006 · Cited by 19
“Although expression of the transgene in the liver is mostly associated with tolerogenic response,(36) in the skeletal muscles it is likely to induce transgene-specific CD8 T cell infiltration into the tissue.(37,38)”
BackgroundWasala, L. P., Watkins, T. B., Wasala, N. B., Burke, M. J., Yue, Y., Lai, Y., Yao, G., & Duan, D. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.180 · Cited by 19
“44,45 Importantly, the presence of H1 in l Dys may underlie severe adverse events seen in clinical trials.”
Heller, K. N., Montgomery, C. L., Shontz, K. M., Clark, K. R., Mendell, J. R., & Rodino‐Klapac, L. R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.062 · Cited by 24
Self-citationGene Replacement Therapy for Genetic Hepatocellular Jaundice
van Dijk, R., Beuers, U. H., & Bosma, P. J. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8454-7 · Cited by 21
Vila, M. C., Novak, J. S., Klimek, M. B., Li, N., Morales, M., Fritz, A. G., Edwards, K. A., Boehler, J., Hogarth, M. W., Kinder, T. B., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5263 · Cited by 21
“Such an immune response has been reported after intramuscular administration to DMD patients of recombinant adeno-associated viral vectors (rAAVs) containing a functional mini-dystrophin transgene, with this treatment initiating a strong T-cell-mediated response to both the vector and dystrophin [16,17].”
BackgroundDavies, K. E. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-6-594 · Cited by 22
rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
Ishii, A., Okada, H., Hayashita-Kinoh, H., Shin, J.-H., Tamaoka, A., Okada, T., & Takeda, S. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.012 · Cited by 18
“As described above, for patients with DMD treated with AAV-mediated gene therapy, T cells reactive against dystrophin are a known complication.(7) In our study, IgM against LacZ was produced 4 weeks after AAV9CMVLacZ injection without tacrolimus.”
BackgroundEgorova, T. V., Starikova, A. V., & Polikarpova, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111492 · Cited by 20
“In clinical trials of AAV2-based minidystrophin no transgene expression was observed after intramuscular delivery of a functional transgene to patients with DMD. Dystrophin-specific T-cell immune responses were detected after treatment [37].”
Yadav, M., Yoo, K. W., Atala, A., & Lu, B. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.009 · Cited by 19
“Immune responses to transgene products have been reported in animal studies,(42,43) as well as in gene therapy clinical trials for a-1-antitrypsin deficiency(44) and Duchenne’s muscular dystrophy.(45) In this study, effects of CLCN5 gene therapy effects lasted for up to 3 months but diminished after 4 months.”
BackgroundLorant, J., Larcher, T., Jaulin, N., Hédan, B., Lardenois, A., Leroux, I., Dubreil, L., Ledevin, M., Goubin, H., Moullec, S., et al. (2018) · Cell Transplantation · doi:10.1177/0963689718776306 · Cited by 18
Defective dystrophic thymus determines degenerative changes in skeletal muscle
Farini, A., Sitzia, C., Villa, C., Cassani, B., Tripodi, L., Legato, M., Belicchi, M., Bella, P., Lonati, C., Gatti, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22305-x · Cited by 19
Inflammation, fibrosis and skeletal muscle regeneration in LGMDR9 are orchestrated by macrophages
Kölbel, H., Preuße, C., Brand, L., von Moers, A., Marina, A. D., Schuelke, M., Roos, A., Goebel, H., Schara, U., & Stenzel, W. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12730 · Cited by 18
Morgan, J. E., & Muntoni, F. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210683 · Cited by 19
“But a major limitation to AAV-mediated gene therapy is that AAV induces an immune response, which makes re-administration a challenge [38, 39].”
BackgroundImmunological Monitoring to Rationally Guide AAV Gene Therapy
Britten, C. M., Walter, S., & Janetzki, S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00273 · Cited by 18
“Also antigenspecific T cells against the encoded therapeutic gene have been described and may reduce efficacy of gene therapy (10).”
BackgroundRobert, M.-A., Nassoury, N., Chahal, P. S., Venne, M.-H., Racine, T., Qiu, X., Kobinger, G., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.101 · Cited by 20
“9,10 15 The utilization of rAAV for antibody therapy could therefore be useful to treat various chronic and infectious diseases.”
Inhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
“However, after direct muscular administration of AAV vectors encoding mini-dystrophin (minidys), we noted a CTL response to the dystrophin, which may relate to revertant fiber development induced prior to gene therapy (34).”
BackgroundSelf-citationProtection is not always a good thing: The immune system’s impact on gene therapy
de Freitas, M. V., Frâncio, L., Haleva, L., & Matte, Ú. D. S. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2022-0046 · Cited by 21
Braun, S. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2747 · Cited by 18
“To date, (i) no serious adverse events; (ii) a low level of local minidystrophin expression; and (iii) some immune response against epitopes that are initially absent in the patients have been observed in the first patients treated [13].”
BackgroundDevelopments in the treatment of hemophilia B: focus on emerging gene therapy
Gray, J. T., Cancio, M., Reiss, U. M., Nathwani, A. C., & Davidoff, A. M. (2013) · The Application of Clinical Genetics · doi:10.2147/tacg.s31928 · Cited by 19
In vitro stability of therapeutically relevant, internally truncated dystrophins
McCourt, J. L., Rhett, K. K., Jaeger, M. A., Belanto, J. J., Talsness, D. M., & Ervasti, J. M. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0040-z · Cited by 17
“The Δ3990 hDys construct corresponds to the AAVdelivered micro-dystrophin used in a clinical trial that reported minimal recombinant dystrophin expression associated with a strong immune response to dystrophin [20,37].”
Peptide-Functionalized Dendrimer Nanocarriers for Targeted Microdystrophin Gene Delivery
Hersh, J., Capcha, J. C., Irion, C. I., Lambert, G., Noguera, M., Singh, M., Kaur, A., Dikici, E., Jimenez, J., Shehadeh, L., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122159 · Cited by 14
Biological and genetic therapies for the treatment of Duchenne muscular dystrophy
Wilton-Clark, H., & Yokota, T. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2150543 · Cited by 18
Exploring the therapeutic potential of modulating nonsense-mediated mRNA decay
McMahon, M., & Maquat, L. E. (2024) · RNA · doi:10.1261/rna.080334.124 · Cited by 17
“One concern regarding all of the therapeutic approaches mentioned in this section is the potential of generating novel immunogenic epitopes in patients related to the restored target protein, as has been observed in DMD upon dystrophin reexpression (Mendell et al. 2010).”
Duan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
Micro-utrophin Therapy for Duchenne Muscular Dystrophy
Duan, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.10.011 · Cited by 16
“One concern of dystrophin replacement therapy is the induction of the cellular immune response by the newly generated dystrophin protein.(4,5) While application of transient immune suppression at the time of gene therapy may minimize the concern of dystrophin immunity,”
BackgroundLi, N., Parkes, J. E., Spathis, R., Morales, M., McDonald, J. W., Kendra, R. M., Ott, E. M., Brown, K. J., Lawlor, M. W., & Nagaraju, K. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210706 · Cited by 16
“There is evidence in both DMD patients and animal models that dystrophin replacement by gene therapy leads to an anti-dystrophin immune response [1, 2] that is likely to limit the long-term use of these therapeutic strategies as has been seen in many other disorders [3].”
(2025) · doi:10.1093/protein/gzaf003 · Cited by 15
“The consequences of disregarding the immune-reaction could range from reduced therapeutic efficacy up to unwanted auto-immune-reactions targeting the therapeutic protein—as demonstrated by anti-transgene immunity (Car-pentier et al., 2015, Mendell et al., 2010).”
Upregulation of utrophin improves the phenotype of Duchenne muscular dystrophy hiPSC-derived CMs
Andrysiak, K., Ferdek, P. E., Sanetra, A. M., Machaj, G., Schmidt, L., Kraszewska, I., Sarad, K., Palus‐Chramiec, K., Lis, O., Targosz‐Korecka, M., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102247 · Cited by 17
Kawano, Y., Neeley, S., Adachi, K., & Nakai, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066211 · Cited by 17
Zhong, H., Zheng, Y., Zhao, Z., Lin, P., Xi, J., Zhu, W., Lin, J., Lü, J., Yu, M., Zhang, W. Y., et al. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107159 · Cited by 17
The Muscular Dystrophies: Distinct Pathogenic Mechanisms Invite Novel Therapeutic Approaches
Sahenk, Z., & Mendell, J. R. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0178-6 · Cited by 18
Self-citationCharacterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry
Kastenschmidt, J. M., Avetyan, I., & Villalta, S. A. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7374-3_4 · Cited by 16
“This growing concern is supported by recent studies by Mendell and colleagues, which showed that a substantial fraction of DMD patients harbor circulating dystrophin-reactive T cells before and after gene therapy [14, 15].”
ResultLu, H., Qu, G., Yang, X., Xu, R., & Xiao, W. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.005 · Cited by 14
“Adeno-associated virus (AAV) vector has shown great promise as a gene therapy vector in human clinical trials (Manno et al., 2006; Brantly et al., 2009; Maguire et al., 2009; Mendell et al., 2010).”
Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer
Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 14
“…skeletal muscle fibers by intramuscular (IM) administration has undergone clinical trials for treatment of different forms of muscular dystrophy [1–3] and for systemic protein delivery (for hemophilia B and α 1 -antitrypsin deficiency, for example) [4,5] and also formed the basis for the first…”
BackgroundKang, S., Lu, K., Leelawattanachai, J., Hu, X., Park, S., Park, T., Min, I. M., & Jin, M. M. (2013) · Gene Therapy · doi:10.1038/gt.2013.29 · Cited by 14
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
Passive Immunization against HIV/AIDS by Antibody Gene Transfer
Yang, L., & Wang, P. (2014) · Viruses · doi:10.3390/v6020428 · Cited by 16
“Thus, various serotypes of AAVs have become the most appealing vectors for in vivo gene therapy [46], and many of them have shown promising results in early-phase clinical trials [47–58].”
BackgroundKistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
Gene therapy in monogenic congenital myopathies
Guan, X., Goddard, M. A., Mack, D. L., & Childers, M. K. (2015) · Methods · doi:10.1016/j.ymeth.2015.10.004 · Cited by 15
Gernoux, G., Guilbaud, M., Devaux, M., Journou, M., Pichard, V., Jaulin, N., Léger, A., Duff, J. L., Deschamps, J., Guiner, C. L., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.003 · Cited by 14
“Induction of Treg-mediated immune modulation after LR delivery might be of particular interest for the treatment of patients with null mutations or patients with pre-existing cellular response to the transgene product.(8) Finally, this administration route could be an alternative to IM or i.”
BackgroundThe potential for Treg-enhancing therapies in tissue, in particular skeletal muscle, regeneration
Hanna, B. S., Yaghi, O., Langston, P. K., & Mathis, D. J. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac076 · Cited by 14
Systemic AAV Gene Therapy Close to Clinical Trials for Several Neuromuscular Diseases
Wells, D. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.006 · Cited by 14
“Clinicaltrials.gov Identifier Trial Route Associated Publications NCT00428935 safety study of mini-dystrophin gene to treat Duchenne muscular dystrophy intramuscular Mendell et al.11 NCT00494195 gene transfer therapy for treating children and adults with limb girdle muscular dystrophy type 2D (LGMD2D) intramuscular Me…”
Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies
Farini, A., Villa, C., Tripodi, L., Legato, M., & Torrente, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666879 · Cited by 13
“The identification of dystrophin autoantibodies in DMD animal models (48, 107) and patients (46, 108) and the rising of IIMsassociated antibodies highlighted new pathomechanisms in the field of myology and suggested a possible role of the autoantibody-mediated activation of the complement cascade.”
BackgroundDivalent Metal Ions Boost Effect of Nucleic Acids Delivered by Cell-Penetrating Peptides
Maloverjan, M., Padari, K., Abroi, A., Rebane, A., & Pooga, M. (2022) · Cells · doi:10.3390/cells11040756 · Cited by 13
“However, in addition to long coding sequences, such as pDNA [5], gene-containing viral vectors [6] and mRNA, shorter nucleic acids, i.”
BackgroundImmune-mediated myositis following gene therapy for Duchenne muscular dystrophy: a case report
Iannaccone, S. T., Cai, C., Rhem, B., Batley, K. Y., Rajaram, V., Greenberg, B. M., Dharia, S. D., & Zaidman, C. M. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12431-z · Cited by 12
Wet-Spun Trojan Horse Cell Constructs for Engineering Muscle
Quigley, A. F., Cornock, R., Mysore, T. B., Foroughi, J., Kita, M., Razal, J. M., Crook, J. M., Moulton, S. E., Wallace, G. G., & Kapsa, R. M. I. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00018 · Cited by 13
“By example, the X-linked congenital Duchenne’s Muscular Dystrophy (DMD), is caused by mutation of the gene encoding the cytoskeletal protein dystrophin results in a lack of functional dystrophin (Mendell et al., 2010), resulting in membrane destabilization and loss of muscle tissue (Blake et al.”
BackgroundT Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy
Anthony, K., Ala, P., Catapano, F., Meng, J., Domingos, J., Perry, M. M., Ricotti, V., Maresh, K. E., Phillips, L. C., Servais, L., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.166 · Cited by 12
“8,9 The assay has also been used to examine T lymphocyte responses to dystrophin in a clinical trial of AAV-minidystrophin, showing that some patients had an immune response either before the start of treatment (2/6 patients) or after treat-ment (4/6 patients).”
Vamva, E., Ozog, S., Leaman, D. P., Cheng, R. Y.-H., Irons, N. J., Ott, A. R., Stoffers, C. M., Khan, I., Goebrecht, G. K. E., Gardner, M. R., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.004 · Cited by 13
“Development of anti-drug antibodies against administered therapeutic proteins is a well-documented complication(85,86) and a potential barrier to gene therapy treatments.(84,87,88) Of interest, reports have documented that gene products fused to IgG and delivered to B cells have proved efficacious in inducing immunoto…”
BackgroundYou, J., Kim, Y., Lee, S., Bashir, R., & Chen, J. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13278 · Cited by 12
“and the immune response against exogenous vectors and proteins.(39,40) Targeting autophagy, as a common modifier of”
BackgroundOu, L., English, K., Tonlorenzi, R., Cossu, G., Tedesco, F. S., & Wood, K. J. (2013) · F1000Research · doi:10.12688/f1000research.2-24.v1 · Cited by 13
Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies
Farini, A., Sitzia, C., Erratico, S., Meregalli, M., & Torrente, Y. (2014) · BioMed Research International · doi:10.1155/2014/818107 · Cited by 12
“[15] J.”
BackgroundInfluentialSurrogate gene therapy for muscular dystrophy
Davies, K. E., & Chamberlain, J. S. (2019) · Nature Medicine · doi:10.1038/s41591-019-0604-2 · Cited by 11
Phoenix rising: gene therapy makes a comeback
Limberis, M. P. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms036 · Cited by 14
“Significant frequencies of circulating transgene-specific T cells have been reported in subjects treated with AAV vectors for various diseases including A1AT deficiency [114] and DMD [116] .”
BackgroundInfluentialOpportunities and challenges for the development of antisense treatment in neuromuscular disorders
van Putten, M., & Aartsma-Rus, A. M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.579098 · Cited by 11
“However, recently, dystrophinspecific T-cells detected by a spot ELISA (ELISPOT) assay were reported in three out of six patients involved in a gene therapy trial, in which patients were given intramuscular injections of different doses of adeno-associated viral vectors containing a microdystrophin gene under a CMV pr…”
Method
Metadata
- Authors
- Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K. R., Li, J., Xiao, X., Samulski, J., McPhee, S. W., Samulski, R. J., & Walker, C. M.
- Affiliations
- Nationwide Children's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- AskBio (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1429-1437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3014106
- OpenAlex
- W2116885047
- Cited by
- 655
- References
- 25
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 38 · 2023: 44 · 2022: 49 · 2021: 42 · 2020: 44 · 2019: 47 · 2018: 31 · 2017: 42 · 2016: 28 · 2015: 47 · 2014: 34 · 2013: 54 · 2012: 60
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI060388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, dystrophin, autoreactive T cells, T cell immunity, dystrophin gene deletion
- MeSH terms
- Dependovirus, Autoantibodies, Child, DNA, Viral, Genetic Vectors, Humans, Immunity, Cellular, Male, T-Lymphocytes, Protein Biosynthesis, Genetic Therapy, Autoimmunity, Dystrophin, Frameshift Mutation, Muscle, Skeletal, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.